Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRV-015 in adults with non-responsive celiac disease
NL-OMON52134Phase 2Active, not recruiting
- Sponsor
- Provention Bio
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ordesekimab in celiac disease and Non-Responsive Celiac Disease (NRCD) (4 arms), sponsored by Provention Bio. Primary endpoint: Absolute change from baseline through Week 24 in abdominal symptoms. Started Feb 2022; status: active, not recruiting.
02
Drugs
ordesekimab
03
Conditions
celiac diseaseNon-Responsive Celiac Disease (NRCD)
Beyond the preview
Go deeper on NL-OMON52134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52134.